Harrison's Internal Medicine > Chapter 12. Pain: Pathophysiology and ManagementPain: Pathophysiology and Management: IntroductionThe task of medicine is to preserve and restore health and to relieve suffering. Understanding pain is essential to both these goals. Because pain is universally understood as a signal of disease, it is the most common symptom that brings a patient to a physician's attention. The function of the pain sensory system is to protect the body and maintain homeostasis. It does this by detecting, localizing, and identifying tissue-damaging processes. Since different diseases produce characteristic patterns of tissue damage, the quality, time course, and location of a patient's pain complaint and the location of tenderness provide important diagnostic clues and are used to evaluate the response to treatment. Once this information is obtained, it is the obligation of the physician to provide rapid and effective pain relief.The Pain Sensory SystemPain is an unpleasant sensation localized to a part of the body. It is often described in terms of a penetrating or tissue-destructive process (e.g., stabbing, burning, twisting, tearing, squeezing) and/or of a bodily or emotional reaction (e.g., terrifying, nauseating, sickening). Furthermore, any pain of moderate or higher intensity is accompanied by anxiety and the urge to escape or terminate the feeling. These properties illustrate the duality of pain: it is both sensation and emotion. When acute, pain is characteristically associated with behavioral arousal and a stress response consisting of increased blood pressure, heart rate, pupil diameter, and plasma cortisol levels. In addition, local muscle contraction (e.g., limb flexion, abdominal wall rigidity) is often present.Peripheral MechanismsThe Primary Afferent NociceptorA peripheral nerve consists of the axons of three different types of neurons: primary sensory afferents, motor neurons, and sympathetic postganglionic neurons (Fig. 12-1). The cell bodies of primary sensory afferents are located in the dorsal root ganglia in the vertebral foramina. The primary afferent axon bifurcates to send one process into the spinal cord and the other to innervate tissues. Primary afferents are classified by their diameter, degree of myelination, and conduction velocity. The largest-diameter fibers, A-beta (Aβ), respond maximally to light touch and/or moving stimuli; they are present primarily in nerves that innervate the skin. In normal individuals, the activity of these fibers does not produce pain. There are two other classes of primary afferents: the small-diameter myelinated A-delta (Aδ) and the unmyelinated (C fiber) axons (Fig. 12-1). These fibers are present in nerves to the skin and to deep somatic and visceral structures. Some tissues, such as the cornea, are innervated only by Aδ and C afferents. Most Aδ and C afferents respond maximally only to intense (painful) stimuli and produce the subjective experience of pain when they are electrically stimulated; this defines them as primary afferent nociceptors (pain receptors). The ability to detect painful stimuli is completely abolished when Aδ and C axons are blocked.
Components of a typical cutaneous nerve. There are two distinct functional categories of axons: primary afferents with cell bodies in the dorsal root ganglion, and sympathetic postganglionic fibers with cell bodies in the sympathetic ganglion. Primary afferents include those with large-diameter myelinated (Aβ), small-diameter myelinated (Aδ), and unmyelinated (C) axons. All sympathetic postganglionic fibers are unmyelinated.Individual primary afferent nociceptors can respond to several different types of noxious stimuli. For example, most nociceptors respond to heating, intense cold, intense mechanical stimuli such as a pinch, and application of irritating chemicals including ATP, serotonin, bradykinin and histamine.SensitizationWhen intense, repeated, or prolonged stimuli are applied to damaged or inflamed tissues, the threshold for activating primary afferent nociceptors is lowered and the frequency of firing is higher for all stimulus intensities. Inflammatory mediators such as bradykinin, nerve growth factor, some prostaglandins, and leukotrienes contribute to this process, which is called sensitization. In sensitized tissues, normally innocuous stimuli can produce pain. Sensitization is a clinically important process that contributes to tenderness, soreness, and hyperalgesia. A striking example of sensitization is sunburned skin, in which severe pain can be produced by a gentle slap on the back or a warm shower.Sensitization is of particular importance for pain and tenderness in deep tissues. Viscera are normally relatively insensitive to noxious mechanical and thermal stimuli, although hollow viscera do generate significant discomfort when distended. In contrast, when affected by a disease process with an inflammatory component, deep structures such as joints or hollow viscera characteristically become exquisitely sensitive to mechanical stimulation.A large proportion of Aδ and C afferents innervating viscera are completely insensitive in normal noninjured, noninflamed tissue. That is, they cannot be activated by known mechanical or thermal stimuli and are not spontaneously active. However, in the presence of inflammatory mediators, these afferents become sensitive to mechanical stimuli. Such afferents have been termed silent nociceptors, and their characteristic properties may explain how under pathologic conditions the relatively insensitive deep structures can become the source of severe and debilitating pain and tenderness. Low pH, prostaglandins, leukotrienes, and other inflammatory mediators such as bradykinin play a significant role in sensitization.Nociceptor-Induced InflammationPrimary afferent nociceptors also have a neuroeffector function. Most nociceptors contain polypeptide mediators that are released from their peripheral terminals when they are activated (Fig. 12-2). An example is substance P, an 11-amino-acid peptide. Substance P is released from primary afferent nociceptors and has multiple biologic activities. It is a potent vasodilator, degranulates mast cells, is a chemoattractant for leukocytes, and increases the production and release of inflammatory mediators. Interestingly, depletion of substance P from joints reduces the severity of experimental arthritis. Primary afferent nociceptors are not simply passive messengers of threats to tissue injury but also play an active role in tissue protection through these neuroeffector functions.
Events leading to activation, sensitization, and spread of sensitization of primary afferent nociceptor terminals. A. Direct activation by intense pressure and consequent cell damage. Cell damage induces lower pH (H+) and leads to release of potassium (K+) and to synthesis of prostaglandins (PG) and bradykinin (BK). Prostaglandins increase the sensitivity of the terminal to bradykinin and other pain-producing substances. B. Secondary activation. Impulses generated in the stimulated terminal propagate not only to the spinal cord but also into other terminal branches where they induce the release of peptides, including substance P (SP). Substance P causes vasodilation and neurogenic edema with further accumulation of bradykinin. Substance P also causes the release of histamine (H) from mast cells and serotonin (5HT) from platelets.Central MechanismsThe Spinal Cord and Referred PainThe axons of primary afferent nociceptors enter the spinal cord via the dorsal root. They terminate in the dorsal horn of the spinal gray matter (Fig. 12-3). The terminals of primary afferent axons contact spinal neurons that transmit the pain signal to brain sites involved in pain perception. When primary afferents are activated by noxious stimuli, they release neurotransmitters from their terminals that excite the spinal cord neurons. The major neurotransmitter they release is glutamate, which rapidly excites dorsal horn neurons. Primary afferent nociceptor terminals also release peptides, including substance P and calcitonin gene-related peptide, which produce a slower and longer-lasting excitation of the dorsal horn neurons. The axon of each primary afferent contacts many spinal neurons, and each spinal neuron receives convergent inputs from many primary afferents.
The convergence-projection hypothesis of referred pain.
According to this hypothesis, visceral afferent nociceptors converge on the same pain-projection neurons as the afferents from the somatic structures in which the pain is perceived. The brain has no way of knowing the actual source of input and mistakenly "projects" the sensation to the somatic structure.The convergence of sensory inputs to a single spinal pain-transmission neuron is of great importance because it underlies the phenomenon of referred pain. All spinal neurons that receive input from the viscera and deep musculoskeletal structures also receive input from the skin. The convergence patterns are determined by the spinal segment of the dorsal root ganglion that supplies the afferent innervation of a structure. For example, the afferents that supply the central diaphragm are derived from the third and fourth cervical dorsal root ganglia. Primary afferents with cell bodies in these same ganglia supply the skin of the shoulder and lower neck. Thus, sensory inputs from both the shoulder skin and the central diaphragm converge on pain-transmission neurons in the third and fourth cervical spinal segments. Because of this convergence and the fact that the spinal neurons are most often activated by inputs from the skin, activity evoked in spinal neurons by input from deep structures is mislocalized by the patient to a place that is roughly coextensive with the region of skin innervated by the same spinal segment. Thus, inflammation near the central diaphragm is usually reported as discomfort near the shoulder. This spatial displacement of pain sensation from the site of the injury that produces it is known as referred pain.Ascending Pathways for PainA majority of spinal neurons contacted by primary afferent nociceptors send their axons to the contralateral thalamus. These axons form the contralateral spinothalamic tract, which lies in the anterolateral white matter of the spinal cord, the lateral edge of the medulla, and the lateral pons and midbrain. The spinothalamic pathway is crucial for pain sensation in humans. Interruption of this pathway produces permanent deficits in pain and temperature discrimination.Spinothalamic tract axons ascend to several regions of the thalamus. There is tremendous divergence of the pain signal from these thalamic sites to broad areas of the cerebral cortex that subserve different aspects of the pain experience (Fig. 12-4). One of the thalamic projections is to the somatosensory cortex. This projection mediates the purely sensory aspects of pain, i.e., its location, intensity, and quality. Other thalamic neurons project to cortical regions that are linked to emotional responses, such as the cingulate gyrus and other areas of the frontal lobes, including the insular cortex. These pathways to the frontal cortex subserve the affective or unpleasant emotional dimension of pain. This affective dimension of pain produces suffering and exerts potent control of behavior. Because of this dimension, fear is a constant companion of pain.
Pain transmission and modulatory pathways. A. Transmission system for nociceptive messages. Noxious stimuli activate the sensitive peripheral ending of the primary afferent nociceptor by the process of transduction. The message is then transmitted over the peripheral nerve to the spinal cord, where it synapses with cells of origin of the major ascending pain pathway, the spinothalamic tract. The message is relayed in the thalamus to the anterior cingulate (C), frontal insular (F), and somatosensory cortex (SS). B. Pain-modulation network. Inputs from frontal cortex and hypothalamus activate cells in the midbrain that control spinal pain-transmission cells via cells in the medulla. Pain ModulationThe pain produced by injuries of similar magnitude is remarkably variable in different situations and in different individuals. For example, athletes have been known to sustain serious fractures with only minor pain, and Beecher's classic World War II survey revealed that many soldiers in battle were unbothered by injuries that would have produced agonizing pain in civilian patients. Furthermore, even the suggestion of relief can have a significant analgesic effect (placebo). On the other hand, many patients find even minor injuries (such as venipuncture) frightening and unbearable, and the expectation of pain has been demonstrated to induce pain without a noxious stimulus.The powerful effect of expectation and other psychological variables on the perceived intensity of pain implies the existence of brain circuits that can modulate the activity of the pain-transmission pathways. One of these circuits has links in the hypothalamus, midbrain, and medulla, and it selectively controls spinal pain-transmission neurons through a descending pathway (Fig. 12-4).Human brain imaging studies have implicated this pain-modulating circuit in the pain-relieving effect of attention, suggestion, and opioid analgesic medications. Furthermore, each of the component structures of the pathway contains opioid receptors and is sensitive to the direct application of opioid drugs. In animals, lesions of the system reduce the analgesic effect of systemically administered opioids such as morphine. Along with the opioid receptor, the component nuclei of this pain-modulating circuit contain endogenous opioid peptides such as the enkephalins and β-endorphin.The most reliable way to activate this endogenous opioid-mediated modulating system is by prolonged pain and/or fear. There is evidence that pain-relieving endogenous opioids are released following surgical procedures and in patients given a placebo for pain relief.Pain-modulating circuits can enhance as well as suppress pain. Both pain-inhibiting and pain-facilitating neurons in the medulla project to and control spinal pain-transmission neurons. Since pain-transmission neurons can be activated by modulatory neurons, it is theoretically possible to generate a pain signal with no peripheral noxious stimulus. In fact, human functional imaging studies have demonstrated increased activity in this circuit during migraine headache. A central circuit that facilitates pain could account for the finding that pain can be induced by suggestion or enhanced by expectation, and it could provide a framework for understanding how psychological factors can contribute to chronic pain.Neuropathic PainLesions of the peripheral or central nervous pathways for pain typically result in a loss or impairment of pain sensation. Paradoxically, damage to or dysfunction of these pathways can produce pain. For example, damage to peripheral nerves, as occurs in diabetic neuropathy, or to primary afferents, as in herpes zoster, can result in pain that is referred to the body region innervated by the damaged nerves. Though rare, pain may also be produced by damage to the central nervous system, particularly the spinothalamic pathway or thalamus. Such neuropathic pains are often severe and are notoriously intractable to standard treatments for pain.Neuropathic pains typically have an unusual burning, tingling, or electric shock–like quality and may be triggered by very light touch. These features are rare in other types of pain. On examination, a sensory deficit is characteristically present in the area of the patient's pain. Hyperpathia is also characteristic of neuropathic pain; patients often complain that the very lightest moving stimuli evoke exquisite pain (allodynia). In this regard it is of clinical interest that a topical preparation of 5% lidocaine in patch form is effective for patients with postherpetic neuralgia who have prominent allodynia.A variety of mechanisms contribute to neuropathic pain. As with sensitized primary afferent nociceptors, damaged primary afferents, including nociceptors, become highly sensitive to mechanical stimulation and begin to generate impulses in the absence of stimulation. There is evidence that this increased sensitivity and spontaneous activity is due to an increased concentration of sodium channels. Damaged primary afferents may also develop sensitivity to norepinephrine. Interestingly, spinal cord pain-transmission neurons cut off from their normal input may also become spontaneously active. Thus, both central and peripheral nervous system hyperactivity contribute to neuropathic pain. Sympathetically Maintained PainPatients with peripheral nerve injury can develop a severe burning pain (causalgia) in the region innervated by the nerve. The pain typically begins after a delay of hours to days or even weeks. The pain is accompanied by swelling of the extremity, periarticular osteoporosis, and arthritic changes in the distal joints. The pain is dramatically and immediately relieved by blocking the sympathetic innervation of the affected extremity. Damaged primary afferent nociceptors acquire adrenergic sensitivity and can be activated by stimulation of the sympathetic outflow. A similar syndrome called reflex sympathetic dystrophy can be produced without obvious nerve damage by a variety of injuries, including fractures of bone, soft tissue trauma, myocardial infarction, and stroke (Chap. 370). Although the pathophysiology of this condition is poorly understood, the pain and the signs of inflammation are rapidly relieved by blocking the sympathetic nervous system. This implies that sympathetic activity can activate undamaged nociceptors when inflammation is present. Signs of sympathetic hyperactivity should be sought in patients with posttraumatic pain and inflammation and no other obvious explanation.Acute Pain: TreatmentThe ideal treatment for any pain is to remove the cause; thus, diagnosis should always precede treatment planning. Sometimes treating the underlying condition does not immediately relieve pain. Furthermore, some conditions are so painful that rapid and effective analgesia is essential (e.g., the postoperative state, burns, trauma, cancer, sickle cell crisis). Analgesic medications are a first line of treatment in these cases, and all practitioners should be familiar with their use.Aspirin, Acetaminophen, and Nonsteroidal Anti-Inflammatory Agents (NSAIDs)These drugs are considered together because they are used for similar problems and may have a similar mechanism of action (Table 12-1). All these compounds inhibit cyclooxygenase (COX), and, except for acetaminophen, all have anti-inflammatory actions, especially at higher dosages. They are particularly effective for mild to moderate headache and for pain of musculoskeletal origin.Table 12-1 Drugs for Relief of Pain
Generic Name | Dose, mg | Interval | Comments |
NONNARCOTIC ANALGESICS: USUAL DOSES AND INTERVALS | |||
Acetylsalicylic acid | 650 PO | q 4 h | Enteric-coated preparations available |
Acetaminophen | 650 PO | q 4 h | Side effects uncommon |
Ibuprofen | 400 PO | q 4–6 h | Available without prescription |
Naproxen | 250–500 PO | q 12 h | Delayed effects may be due to long half-life |
Fenoprofen | 200 PO | q 4–6 h | Contraindicated in renal disease |
Indomethacin | 25–50 PO | q 8 h | Gastrointestinal side effects common |
Ketorolac | 15–60 IM/IV | q 4–6 h | Available for parenteral use |
Celecoxib | 100–200 PO | q 12–24 h | Useful for arthritis |
Valdecoxib | 10–20 PO | q12–24 h | Removed from U.S. market in 2005 |
Generic Name | Parenteral Dose, mg | PO Dose, mg | Comments |
NARCOTIC ANALGESICS: USUAL DOSES AND INTERVALS | |||
Codeine | 30–60 q 4 h | 30–60 q 4 h | Nausea common |
Oxycodone | — | 5–10 q 4–6 h | Usually available with acetaminophen or aspirin |
Morphine | 10 q 4 h | 60 q 4 h | |
Morphine sustained release | — | 30–200 bid to tid | Oral slow-release preparation |
Hydromorphone | 1–2 q 4 h | 2–4 q 4 h | Shorter acting than morphine sulfate |
Levorphanol | 2 q 6–8 h | 4 q 6–8 h | Longer acting than morphine sulfate; absorbed well PO |
Methadone | 10 q 6–8 h | 20 q 6–8 h | Delayed sedation due to long half-life |
Meperidine | 75–100 q 3–4 h | 300 q 4 h | Poorly absorbed PO; normeperidine a toxic metabolite |
Butorphanol | — | 1–2 q 4 h | Intranasal spray |
Fentanyl | 25–100 µg/h | — | 72 h Transdermal patch |
Tramadol | — | 50–100 q 4–6 h | Mixed opioid/adrenergic action |
Generic Name | Uptake Blockade | Sedative Potency | Anticholinergic Potency | Orthostatic Hypotension | Cardiac Arrhythmia | Ave. Dose, mg/d | Range, mg/d | |
5-HT | NE | |||||||
ANTIDEPRESSANTSa | ||||||||
Doxepin | ++ | + | High | Moderate | Moderate | Less | 200 | 75–400 |
Amitriptyline | ++++ | ++ | High | Highest | Moderate | Yes | 150 | 25–300 |
Imipramine | ++++ | ++ | Moderate | Moderate | High | Yes | 200 | 75–400 |
Nortriptyline | +++ | ++ | Moderate | Moderate | Low | Yes | 100 | 40–150 |
Desipramine | +++ | ++++ | Low | Low | Low | Yes | 150 | 50–300 |
Venlafaxine | +++ | ++ | Low | None | None | No | 150 | 75–400 |
Duloxetine | +++ | +++ | Low | None | None | No | 40 | 30–60 |
Generic Name | PO Dose, mg | Interval | Generic Name | PO Dose, mg | Interval |
ANTICONVULSANTS AND ANTIARRHYTHMICSa | |||||
Phenytoin | 300 | daily/qhs | Clonazepam | 1 | q 6 h |
Carbamazepine | 200–300 | q 6 h | Gabapentinb | 600–1200 | q 8 h |
Oxcarbazine | 300 | bid | Pregabalin | 150–600 | bid |
Postherpetic neuralgiaa |
Diabetic neuropathya |
Tension headachea |
Migraine headachea |
Rheumatoid arthritisa,b |
Chronic low back painb |
Cancer |
Central post-stroke pain |
Craig AD: How do you feel? Interoception: The sense of the physiological condition of the body. Nat Rev Neurosci 8:655, 2002 |
Fields HL: Should we be reluctant to prescribe opioids for chronic nonmalignant pain? Pain 129:233, 2007 [PMID: 17449177] |
Keltner JR et al: Isolating the modulatory effect of expectation on pain transmission: A functional magnetic resonance imaging study. J Neurosci 26:4437, 2006 [PMID: 16624963] |
Macintyre PE: Safety and efficacy of patient-controlled analgesia. Br J Anaesth 87:36, 2001 [PMID: 11460812] |
Wager TD et al: Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303:1162, 2004 [PMID: 14976306] |
Baliki MN et al: Chronic pain and the emotional brain: Specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. J Neurosci 26:12165, 2006 [PMID: 17122041] |
Baron R et al: Causalgia and reflex sympathetic dystrophy: Does the sympathetic nervous system contribute to the generation of pain? Muscle Nerve 22:678, 1999 [PMID: 10366221] |
Gebhart GF (ed): Visceral Pain. Seattle, IASP Press, 1995 |
Gilron I et al: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352:1324, 2005 [PMID: 15800228] |
Julius D, Basbaum AI: Molecular mechanisms of nociception. Nature 413:203, 2001 [PMID: 11557989] |
Kearney PM: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332:1302, 2006 [PMID: 16740558] |
McMahon SB, Koltzenburg M (eds): Wall and Melzack's Textbook of Pain, 5th ed. Philadelphia: Elsevier/Churchill Livingstone, 2006 |
Rush AM et al: A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Nat Acad Sci U.S.A. 103:8245, 2006 [PMID: 16702558] |
Wallace MS: Diagnosis and treatment of neuropathic pain. Curr Opin Anaesthesiol 18:548, 2005 [PMID: 16534291] |
Không có nhận xét nào:
Đăng nhận xét